News & Articles

New research assesses the interaction between the SARS-CoV-2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) and heparin

Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019

Investment in state-of-the-art automation cements Abingdon Health’s position as a leading global rapid test manufacturer

“The NHC is uniquely positioned to flourish in the biotech ecosystem, with capabilities to respond to, and partner with organisations to solve the grand challenges of the bioscience industry.

Multiyear alliance underpins Randox commitment to increase biochip manufacturing to transform rapid diagnostic testing

The collaboration also includes the University of Coventry, UCB, and is supported by EIT Digital.

The company is providing well-characterized and standardized human primary cells with matching specialty cell culture media

Additional real-world data demonstrate meaningful outcomes for people living with diabetes who use Abbott's glucose sensing technology

The RECOVERY trial has shown that the cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19

Lonza has collaborated with CELLINK to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to advance complete 3D cell culture workflows

The test detects antibodies made by the immune system in response to infection by the novel coronavirus in as little as 10 minutes

Companies team-up to promote the use of protein footprinting technologies, products, and contract research services in biopharmaceutical research and development

It's comprehensive SARS-COV-2 offerings span RT-PCR, high throughput RNA extraction, automation, ELISA and lateral flow based serology testing.

30 stories from customers, partners and employees celebrate the past and look ahead to joint success in the future

Clinical researchers are this week set to begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London

The production agreement is part of AstraZeneca’s recently announced in-licensed programme with the University of Oxford